Iskalni niz:
išči po
išči po
išči po
išči po
Vrsta gradiva:
Jezik:
Št. zadetkov: 2
[111In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer
Luka Ležaič, Paola Erba, Clemens Decristoforo, Katja Zaletel, Renata Mikolajczak, Helmut R. Maecke, Theodosia Maina, Mark W. Konijnenberg, Petra Kolenc-Peitl, Malgorzata Trofimiuk‑Müldner
Izvirni znanstveni članek
Oznake: onkologija;rak ščitnice;molekularni pregled;terapija;
Introduction: Medullary thyroid cancer (MTC) is a rare malignant tumour of the parafollicular C-cells with an unpredictable clinical course and currently suboptimal diagnostic and therapeutic options, in particular in advanced disease. Overexpression of cholecystokinin-2 receptors (CCK2R) represents ...
Leto: 2023 Vir: Digitalni repozitorij raziskovalnih organizacij Slovenije
Development of the 99mTc-labelled SST2 antagonist TECANT-1 for a first-in-man multicentre clinical study
Doroteja Novak, Barbara Janota, Anton Amadeus Hörmann, Agnieszka Sawicka, Marko Krošelj, Alicja Hubalewska-Dydejczyk, Melpomeni Fani, Renata Mikolajczak, Petra Kolenc-Peitl, Clemens Decristoforo, Piotr Garnuszek
Izvirni znanstveni članek
Oznake: tehnecij-99m;antagonisti receptorjev somatostatina;formulacija kompleta;toksičnost enkratnega odmerka;SPECT;radiofarmacevtiki;nevroendokrine neoplazme;technetium-99m;somatostatin receptor antagonists;kit formulation;single dose toxicity;radiopharmaceuticals;neuroendocrine neoplasms;
Broad availability and cost-effectiveness of 99Mo/99mTc generators worldwide support the use, and thus the development, of novel 99mTc-labelled radiopharmaceuticals. In recent years, preclinical and clinical developments for neuroendocrine neoplasms patient management focused on somatostatin recepto ...
Leto: 2023 Vir: Fakulteta za farmacijo (UL FFA)
Št. zadetkov: 2
Ključne besede:
Leto izdaje:
Avtorji:
Repozitorij:
Tipologija:
Jezik: